Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1557939/000155793915000060/a2015q310q.htm
September 2016
September 2016
August 2016
July 2016
June 2016
June 2016
May 2016
April 2016
March 2016
February 2016
![]() | ![]() |
• | Revenue of $477.7 million, down 0.9% as reported on a GAAP basis from the prior-year period and grew 3.3% on a constant currency basis |
• | Revenue from Advanced Wound Therapeutics (“AWT”), down 1.9% as reported on a GAAP basis, grew 3.1% on a constant currency basis, led by mid-single digit volume increases compared to the prior-year period |
• | Revenue from Regenerative Medicine (“RM”) grew 4.5% as reported on a GAAP basis, and 5.9% on a constant currency basis, led by high-single digit increases in revenue related to breast reconstruction procedures |
• | Operating earnings of $106.1 million, up 20.0% as reported on a GAAP basis from $88.3 million in the prior-year period |
• | Adjusted EBITDA from continuing operations1 of $187.5 million, down 2.3% as reported from the prior-year period and grew 0.9% on a constant currency basis, achieving an Adjusted EBITDA margin of 39.2% |
• | Reinforced the strategy of geographic expansion with double-digit growth in advanced wound dressings, driven by strong performance in markets outside the U.S. In addition, Acelity entered into a strategic commercial partnership with GHD GesundHeits GmbH Deutschland (“GHD”) to distribute Acelity’s advanced wound dressings portfolio in Germany. The partnership with GHD, the largest provider of homecare services in Germany, offers Acelity access to serve GHD’s breadth of customers in both acute and post-acute care settings. |
• | Expanded our product offerings in Brazil by obtaining approval to sell StratticeTM, an acellular reconstructive tissue matrix designed to assist in soft-tissue procedures to reinforce tissue where weakness exists and promote tissue regeneration. |
• | Expanded Acelity’s industry-leading product portfolio with additions to three renowned brands in order to provide clinicians more options when treating patients— Strattice™ Reconstructive Tissue Matrix Perforated (U.S.), a shorter Prevena™ dressing for smaller, anatomically-challenging incisions (U.S. and Europe) and TIELLE® Silicone Border (Europe), a hydropolymer foam dressing for increased patient comfort with exudate absorption. |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1557939/000155793915000060/a2015q310q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Acelity L.P. Inc..
Acelity L.P. Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Acelity L.P. Inc. provided additional information to their SEC Filing as exhibits
CIK: 1557939
Form Type: 10-Q Quarterly Report
Accession Number: 0001557939-15-000060
Submitted to the SEC: Wed Oct 28 2015 5:01:24 PM EST
Accepted by the SEC: Wed Oct 28 2015
Period: Wednesday, September 30, 2015
Industry: Surgical And Medical Instruments And Apparatus